A Randomized, Double-blind, Multi-center, Placebo Parallel controlled, Standard Therapy Based Phase II Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Injection.

Trial Profile

A Randomized, Double-blind, Multi-center, Placebo Parallel controlled, Standard Therapy Based Phase II Clinical Trial to Evaluate the Efficacy and Safety of Recombinant Human Neuregulin-1 for Injection.

Completed
Phase of Trial: Phase II

Latest Information Update: 24 Apr 2016

At a glance

  • Drugs Recombinant human neuregulin 1-beta (Primary)
  • Indications Chronic heart failure
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 23 May 2013 Pooled phase II results published in a Zensun Sci & Tech media release.
    • 21 May 2012 Actual end date changed from 1 Jan 2009 to 31 May 2009, as reported by Chinese Clinical Trial Register.
    • 27 Apr 2010 Results published in Journal of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top